Evotec and Almirall sign AI drug discovery deals as tech capital pushes fail-fast development
Evotec signed an AI drug discovery deal with Odyssey Therapeutics for inflammatory diseases, and Almirall is to use CrystalO's platform to discover ion channel drugs. According to BioSpace, tech capital is pushing biopharma toward fail-fast development (August 10–12).
Who is affected and how
- pharmaceuticals
- The contract and milestone terms of AI-biotech partnerships should also be weighed against the expectations of tech investors.
Sources
- Evotec inks AI drug discovery deal with Odyssey Therapeutics for inflammatory diseases | HealthCare Middle East & Africa - No.1 Health & Pharma Manufacturing Industry Publicationhealthcaremea.com · Aug 10, 2026
- Almirall taps CrystalO's AI platform to discover ion channel drugs for skin diseaseallsci.com · Aug 10, 2026
- With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development - BioSpacebiospace.com · Aug 12, 2026
- With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug developmentbiospace · Aug 12, 2026
- AI biotechs push biopharma toward fail-fast drug development with tech capital backingcompleteaitraining.com · Aug 12, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.